Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks
CONCORDBIO
CONCORDBIO
1,344.80+6.4 (+0.48%)
17 Jul, 12:00 AM

Stock Scores

Quality Score

82.7 / 100

Value Score

21.3 / 100

Price Momentum Score

40.7 / 100

QVM Score

42.7 / 100

Key Metrics

Market Cap
14068.80
P/E (TTM)
53.92
P/B
6.97
P/S (TTM)
13.34
EV/EBITDA
37.10
CAPE (5Y)
51.95
ROE (TTM)
13.63
ROCE (TTM)
15.28
ROA (TTM)
12.22
Avg 3Y ROE
19.25
Earnings 3Y CAGR
2.59
Sales 3Y CAGR
7.33
Sales 5Y CAGR
11.32
Debt/Equity
0.00
Consensus TP
1220.00
Strong Buy %
33.33
Promoter Holding
44.08
Pledged %
0.00

Share Price

Track Concord Biotech Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.

1 Week returns: 3.07 %
Low
1,269.0
High
1,365.6
1 Month returns: 0.36 %
Low
1,250.1
High
1,378.0
1 Year returns: -29.98 %
Low
987.0
High
1,980.0
3 Year CAGR: –
5 Year CAGR: –
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.

Financial Snapshot

See detailed analysis

Multi-year trends for Concord Biotech Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Concord Biotech Ltd. Shareholding Pattern

Quarterly breakdown of Concord Biotech Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Concord Biotech Ltd. shares as reported to NSE and BSE.

Frequently Asked Questions

What is the current share price of Concord Biotech Ltd.?
The current share price of Concord Biotech Ltd. is ₹ 1,344.80 as of 17 Jul 2026.
What is the market capitalisation of Concord Biotech Ltd.?
The market capitalisation of Concord Biotech Ltd. stands at ₹ 14,068.80 Cr.
What is the PE ratio of Concord Biotech Ltd.?
The Price-to-Earnings (PE) ratio of Concord Biotech Ltd. is 53.92 as of the latest trailing twelve months data.
What is the ROE and ROCE of Concord Biotech Ltd.?
Concord Biotech Ltd. has a Return on Equity (ROE) of 13.63% and a Return on Capital Employed (ROCE) of 15.28% as per the latest financial reports.
What is the 52-week high and low of Concord Biotech Ltd.?
The 52-week high of Concord Biotech Ltd. is - and the 52-week low is -.
What is the dividend yield of Concord Biotech Ltd.?
The dividend yield of Concord Biotech Ltd. is 0.80% based on the current market price.
What is the FII and DII holding in Concord Biotech Ltd.?
Foreign Institutional Investors (FII) hold 7.79%, Domestic Institutional Investors (DII) hold 8.19% and retail/public investors hold 36.87% of Concord Biotech Ltd. shares.
What sector does Concord Biotech Ltd. belong to?
Concord Biotech Ltd. operates in the Healthcare sector. 66.67% of analysts have a Buy or Strong Buy rating on Concord Biotech Ltd. with a consensus target price of ₹ 1,220.00, implying 9.28% downside from current levels.
What is the beta of Concord Biotech Ltd.?
The beta of Concord Biotech Ltd. is 0.86, indicating its price volatility relative to the broader market. Over the past 1 year, Concord Biotech Ltd. has delivered an absolute return of -26.09%.
What is the RSI of Concord Biotech Ltd.?
The 14-day Relative Strength Index (RSI) of Concord Biotech Ltd. is 61.53, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.